Cargando…
TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report
SCLC transformation in EGFR-mutated lung adenocarcinoma is one of the major phenotypic changes that is observed during the resistance to EGFR tyrosine kinase inhibitors. However, the mechanism of this transformation remains unclear. In this study, we found a small de novo SCLC component in surgicall...
Autores principales: | Kunimasa, Kei, Hirotsu, Yosuke, Amemiya, Kenji, Nakamura, Harumi, Nishino, Kazumi, Honma, Keiichiro, Okami, Jiro, Omata, Masao, Kumagai, Toru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052150/ https://www.ncbi.nlm.nih.gov/pubmed/35498386 http://dx.doi.org/10.1016/j.jtocrr.2022.100305 |
Ejemplares similares
-
Genetic dissection of intratumor heterogeneity of PD‐L1 expression in
EGFR
‐mutated lung adenocarcinoma
por: Kunimasa, Kei, et al.
Publicado: (2023) -
Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2021) -
Comparison of sampling methods for next generation sequencing for patients with lung cancer
por: Kunimasa, Kei, et al.
Publicado: (2022) -
Genome analysis of peeling archival cytology samples detects driver mutations in lung cancer
por: Kunimasa, Kei, et al.
Publicado: (2020) -
HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1
por: Kumagai, Toru, et al.
Publicado: (2018)